BriaCell Therapeutics Corp. - Common Shares (BCTX)
Healthcare › Pharmaceutical Preparations
Investment Snapshot
- P/B of 0.46 — trading below book value
- Moderate leverage — D/E ratio of 1.25
- Loss-making — negative ROE of -151.8%
BriaCell Therapeutics Corp. - Common Shares (BCTX) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $31 million . Key value metrics: P/B ratio 0.46.
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
BriaCell Therapeutics Corp. - Common Shares — Fundamental Analysis Summary
On financial health, BCTX shows negative return on equity of -151.8% (sector average: -19.8%), and elevated leverage with a debt-to-equity ratio of 1.25.
StockPik's composite Value Score for BCTX is 60/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.